Allos Therapeutics Inc. Third Quarter Earnings Sneak Peek

Allos Therapeutics, Inc. (NASDAQ:ALTH) will unveil its latest earnings on Thursday, November 3, 2011. Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.

Allos Therapeutics, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 15 cents per share, a narrower loss from the year earlier quarter net loss of 18 cents. During the past three months, the average estimate has moved down from a loss of 14 cents. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 16 cents, reporting profit of 2 cents per share against a mean estimate of a loss of 14 cents per share.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Wall St. Revenue Expectations: On average, analysts predict $12.7 million in revenue this quarter, a rise of 54.2% from the year ago quarter. Analysts are forecasting total revenue of $63 million for the year, a rise of 78.8% from last year’s revenue of $35.2 million.

Analyst Ratings: Analysts seem relatively indifferent about Allos Therapeutics with three of four analysts surveyed maintaining a hold rating.

A Look Back: In the second quarter, the company swung to a profit of $2.2 million (2 cents a share) from a loss of $20 million (19 cents) a year earlier, beating analyst estimates. Revenue rose more than fourfold to $39.1 million from $7.9 million.

Key Stats:

Allos Therapeutics’ profit last quarter followed losses in the three previous quarters. The company reported a loss of $15.2 million in the first quarter, a loss of $18.1 million in the fourth of the last fiscal year and a loss of $18.8 million in the third quarter of the last fiscal year.

Revenue has gone up for three straight quarters. It rose 46.7% in the first quarter from the year earlier and more than threefold in the fourth quarter of the last fiscal year.

Competitors to Watch: Seattle Genetics, Inc. (NASDAQ:SGEN), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Hospira, Inc. (NYSE:HSP), Mylan Inc. (NASDAQ:MYL), Cell Therapeutics, Inc. (NASDAQ:CTIC), Cephalon, Inc. (NASDAQ:CEPH), Celgene Corporation (NASDAQ:CELG) and Biogen Idec Inc. (NASDAQ:BIIB).

Stock Price Performance: During September 30, 2011 to October 28, 2011, the stock price had dropped 33 cents (-18%) from $1.83 to $1.50. The stock price saw one of its best stretches over the last year between November 12, 2010 and November 22, 2010 when shares rose for seven-straight days, rising 12.9% (+52 cents) over that span. It saw one of its worst periods between November 22, 2010 and December 3, 2010 when shares fell for nine-straight days, falling 13.4% (-61 cents) over that span. Shares are down $3.11 (-67.5%) year to date.

(Source: Xignite Financials)

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.